Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

746.20 -38.73 (-4.93%)
Official Closing Price Updated: 7:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,334,727
Open 775.19
Bid (Size) 745.50 (1)
Ask (Size) 747.00 (1)
Prev. Close 784.93
Today's Range 744.20 - 777.98
52wk Range 561.65 - 972.53
Shares Outstanding N/A
Dividend Yield 0.61%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Mergers and acquisitions could make a comeback with Trump headed back to Washington. 
Via The Motley Fool
Topics Government
Exposures Political
AskSlim Market Week - Friday, Nov. 15
An analysis and commentary on the financial markets. 
Via Talk Markets

Performance

YTD
+26.00%
+26.00%
1 Month
-18.57%
-18.57%
3 Month
-19.08%
-19.08%
6 Month
-3.09%
-3.09%
1 Year
+26.74%
+26.74%

More News

Read More
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
Via Benzinga
Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Eli Lilly Unusual Options Activity For November 13
Via Benzinga
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Via The Motley Fool
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Via Benzinga
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
2 Top Growth Stocks to Buy on the Dip
Via The Motley Fool
3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years
Via The Motley Fool
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Via Benzinga
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Via The Motley Fool
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
Via Benzinga
2 S&P 500 Dividend Stocks That Could Soar 30% or More, According to a Pair of Wall Street Analysts
Via The Motley Fool
Topics Stocks
Exposures US Equities
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Via Benzinga
Tradepulse Power Inflow Alert: Eli Lilly & Company Moves Up Over 13 Points After Signal
Via Benzinga
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
Via Investor's Business Daily
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Via Benzinga
3 Top Stocks Crushing Q3 Earnings With Strong 2024 Guidance
Via MarketBeat
Biotech Stocks Are Rallying: What Is Your Playbook?
Via Talk Markets
Tesla Remains Core For Gary Black Despite Price Cuts, Earnings Drop — Nvidia, Google, Eli Lilly Among Top Performers In Tech Bull's Portfolio
Via Benzinga
Topics Electric Vehicles
Exposures Electric Vehicles
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Via The Motley Fool
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
Via The Motley Fool
Is Viking Therapeutics a Buy on the Dip?
Via The Motley Fool
MarketBeat Week in Review – 11/4 - 11/8
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.